IGF-1 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

IGF-1 (Insulin-Like Growth Factor 1)

Also known as: Insulin-Like Growth Factor 1, IGF-1, Somatomedin C, MGF (mechano growth factor, an isoform)

Endogenous polypeptide growth factor / anabolic hormone

Research chemicalLast updated: October 19, 2026Based on 44 peer-reviewed studies

What it is

IGF-1 is a natural growth factor the body makes in response to growth hormone; synthetic versions are used by athletes for muscle building and are studied for neurological and metabolic diseases. A pharmaceutical form is FDA-approved for rare severe growth failure in children. Prescription-only for that indication; banned by WADA in sport.

The scientific side

IGF-1 is described as the principal mediator of growth hormone (GH), playing a crucial role in promoting cell growth and differentiation in childhood and exerting anabolic effects in adults. IGF-1 binds specifically to the type 1 IGF receptor (IGF-1R), transmitting intracellular signals through insulin receptor substrate (IRS) and Src homology collagen (Shc) proteins, which activate two major pathways: the phosphatidylinositol 3-kinase (PI3K)/AKT pathway and the mitogen-activated protein kinase (MAPK)/ERK pathway. These downstream cascades regulate cell proliferation, survival, differentiation, apoptosis, and metabolism (PMID 33557137; PMID 34452353). The bioavailability of circulating IGF-1 is regulated by six IGF-binding proteins (IGFBPs), which bind approximately 98% of all circulating IGF-1 with affinity equal to or greater than that of IGF-1R itself. IGF-1 is produced mainly in the liver by GH signaling and also acts as an autocrine/paracrine factor in multiple tissues (PMID 35297369; PMID 41153350). Its actions encompass regulation of cell growth, differentiation, energy metabolism, immune modulation, and neuroprotection (PMID 41153350; PMID 36503467; PMID 34452353).

Class: Endogenous polypeptide growth factor / anabolic hormone

Administration & storage

Administration
Subcutaneous injection (local administration at wound site in mouse model) (PMID: 33895582)
Storage
No abstracts in the reviewed literature explicitly describe storage conditions for IGF-1.
Cautions
IGF-1 is described as a popular doping agent in sport and has featured in many high-profile doping cases; its detection is complicated by IGFBPs which significantly reduce immunoreactive IGF-1 levels in samples.,The existence of multiple IGF-binding proteins (IGFBPs) and IGFBP-related proteins means that total versus free IGF-1 measurements can yield discordant results, complicating interpretation of assay findings.,IGF-1 signaling has been implicated in the promotion of multiple cancers including prostate, breast, hepatocellular, colorectal, and multiple myeloma; elevated IGF-1 was associated with poor prognosis in HCC (PMID: 35297369; PMID: 41184420; PMID: 34208601).,Congenital IGF-1 deficiency (Laron syndrome) is associated with protection from cancer, highlighting the oncogenic potential of IGF-1 signaling at elevated levels.,No human pharmacokinetic, dosing safety, or clinical trial safety data for exogenously administered IGF-1 were present in the reviewed abstracts. Sterile technique is essential for any injectable compound.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification. Note: One abstract mentions 'FDA has recently approved a drug against ADPKD' in a different context, but no abstract explicitly states FDA approval…

WADA

IGF-1 is described as 'a popular doping agent in sport' that 'has featured in many high-profile doping cases in recent years', but the abstract does not explicitly state WADA prohibition status — requires manual…

Health Canada

Not stated in reviewed literature — requires manual verification